PharmaCyte Biotech (PMCB) Other Operating Expenses (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Other Operating Expenses of $1.5 million for Q2 2026, up 233.49% quarter-over-quarter from -$1.2 million in Q2 2024.
PharmaCyte Biotech (PMCB) Other Operating Expenses (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Other Operating Expenses for 16 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses changed N/A year-over-year to $1.5 million; the TTM figure through Apr 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was -$2.0 million, down 28.42% from the prior year.
- Other Operating Expenses improved to $1.5 million in Q2 2026 per PMCB's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $2.0 million in Q4 2022 and bottomed at -$1.2 million in Q2 2024.
- Historically, Other Operating Expenses has averaged $900518.0 across 4 years, with a median of $1.1 million in 2023.
- Annual changes were most pronounced in 2022 — Other Operating Expenses surged 220.42% — and 2024, when it tumbled 337.21%.
- PharmaCyte Biotech's Other Operating Expenses stood at $2.0 million in 2022, then sank by 46.11% to $1.1 million in 2023, then slumped by 210.02% to -$1.2 million in 2024, then jumped by 233.49% to $1.5 million in 2026.
- Business Quant data shows PMCB's Other Operating Expenses at $1.5 million in Q2 2026, -$1.2 million in Q2 2024, and $1.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.55 Mn |
| Apr 30, 2024 | -1.16 Mn |
| Jan 31, 2024 | 1.49 Mn |
| Oct 31, 2023 | 1.05 Mn |
| Jul 31, 2023 | 615,441.00 |
| Apr 30, 2023 | 489,329.00 |
| Jan 31, 2023 | 1.15 Mn |
| Oct 31, 2022 | 1.96 Mn |
| Jul 31, 2022 | 1.28 Mn |
| Apr 30, 2022 | 999,225.00 |
| Jan 31, 2022 | 482,765.00 |
| Oct 31, 2021 | 610,948.00 |
| Jul 31, 2021 | 517,792.00 |
| Apr 30, 2021 | 587,878.00 |
| Jan 31, 2021 | 497,768.00 |
| Oct 31, 2020 | 710,191.00 |
| Jul 31, 2020 | 492,750.00 |
| Apr 30, 2020 | 477,368.00 |
| Jan 31, 2020 | 601,806.00 |
| Oct 31, 2019 | 644,454.00 |